PrEP Truvada Oral denied as non-formulary by Cigna?

Cigna's specific coverage criteria for prep truvada oral are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied PrEP (Truvada) as Non-Formulary

A non-formulary denial means oral Truvada is not on Cigna's preferred drug list for your specific plan, or is placed at a tier that makes it effectively inaccessible due to cost-sharing. This is a common barrier for PrEP medications because formulary placement varies significantly across Cigna plan designs. However, non-formulary status is not the end of the road: formulary exception processes exist precisely for situations where the formulary alternative is clinically inferior or otherwise inappropriate for a specific patient.

## Why This Denial Is Appealable

Cigna must offer a formulary exception process under ACA requirements. If your prescriber can document that no formulary alternative is clinically appropriate for you — or that the formulary alternative is contraindicated, less effective, or otherwise unsuitable based on your clinical profile — you are entitled to have oral Truvada covered at in-formulary cost-sharing. Additionally, if Cigna's formulary lacks a PrEP option entirely, there are separate arguments grounded in the ACA's preventive-services mandate (USPSTF Grade A).

## Federal Appeal Framework

• Formulary exception request: This is the first step and often faster than a formal appeal. Your prescriber submits a request (often via phone or portal) documenting why the formulary alternative is inappropriate.
• Internal appeal (ACA §2719 / ERISA §503): If the exception is denied, you have the right to a full-and-fair internal appeal. Preserve the deadline stated on the denial notice.
• External review: If the internal appeal fails, an independent IRO may review the determination at no cost to you, generally within four months of the final denial. Expedited review is available when medically urgent.
• ACA preventive-services argument: For non-grandfathered plans, separately assert that PrEP is a mandated no-cost preventive service; cost-sharing barriers for USPSTF Grade A services face their own legal challenge.

## Concrete Appeal Process and Timeline

1. Identify the formulary alternative(s) Cigna has designated for PrEP on your plan. 2. Have your prescriber document in the chart why the alternative is not appropriate for you. 3. Submit a formulary exception request with supporting clinical notes. 4. If denied, escalate to a formal internal appeal. 5. If internal appeal fails, file for external IRO review within the stated window.

## Documentation to Gather

• Formulary alternative evaluation: Prescriber's written explanation of why any Cigna-preferred PrEP agent is clinically inferior, contraindicated, or otherwise inappropriate for your specific situation — grounded in your chart, not generalities.
• Clinical history: Records of any prior PrEP use, relevant comorbidities, renal function monitoring history, or other factors your prescriber cites as driving the choice of oral Truvada specifically.
• HIV-negative status and risk documentation: Current labs and clinical notes establishing PrEP candidacy.
• Prescriber medical-necessity letter: Explicit statement that oral Truvada is medically necessary and that formulary alternatives are not clinically equivalent for this patient.

## Criteria-Mapping Structure

Obtain Cigna's formulary exception criteria and complete this table:

| Cigna Exception Criterion | Supporting Clinical Evidence | |---|---| | [Copy exact language from denial or policy] | [Specific chart fact, note date, or prescriber statement] |

A formulary exception that maps each criterion to a specific chart fact is substantially more likely to succeed than a generic "my doctor prefers this drug" letter.